Fidelity National Financial Announces Quarterly Cash Dividend of $0.50

PR Newswire


JACKSONVILLE, Fla.
, May 8, 2025 /PRNewswire/ — Fidelity National Financial, Inc. (NYSE: FNF) (“FNF”) today announced that its Board of Directors has declared a quarterly cash dividend of $0.50 per share of common stock. The dividend will be payable June 30, 2025, to stockholders of record as of June 16, 2025.


About Fidelity National Financial, Inc.

Fidelity National Financial, Inc. (NYSE: FNF) is a leading provider of title insurance and transaction services to the real estate and mortgage industries, and a leading provider of insurance solutions serving retail annuity and life customers and institutional clients through its majority owned subsidiary F&G Annuities & Life, Inc. (NYSE: FG). FNF is the nation’s largest title insurance company through its title insurance underwriters – Fidelity National Title, Chicago Title, Commonwealth Land Title, Alamo Title and National Title of New York – that collectively issue more title insurance policies than any other title company in the United States. More information about FNF can be found at www.fnf.com.

FNF-G

Cision View original content:https://www.prnewswire.com/news-releases/fidelity-national-financial-announces-quarterly-cash-dividend-of-0-50–302449309.html

SOURCE Fidelity National Financial, Inc.

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.

Conference Call and Webcast Information:

  • Date: Monday, May 12, 2025 at 4:30 PM ET
  • Participant Dial-in (US): 1-877-407-0792
  • Participant Dial-in (International): 1-201-689-8263
  • Conference: 13753596
  • Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational product for compulsion-related disorders including Tourette’s Syndrome and Prader-Willi Syndrome, into further studies.

For more information, visit www.relmada.com. Follow us on LinkedIn.

Investor Contact:

Brian Ritchie
LifeSci Advisors
[email protected]

Media Inquiries:

Corporate Communications
[email protected]



Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

– Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 –

– Cybin’s growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending applications –

– Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder (“MDD”) –

– Second Phase 3 study, EMBRACE, is expected to begin mid-2025 –

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD.

The patent, which is expected to provide exclusivity until 2041, includes claims to pharmaceutical compositions and oral dosage forms within the Company’s proprietary deuterated psilocin analog program, CYB003.

“Securing an additional patent in support of CYB003 provides important validation of our program and reinforces the commercial potential of our pipeline,” said Doug Drysdale, Chief Executive Officer of Cybin. “Robust patent protection is essential for drug development companies, and we are proud of our expanding intellectual property portfolio. As we continue to dose patients in our first Phase 3 study, we are focused on execution, delivering shareholder value, and ultimately, creating more effective treatments for those with mental health disorders.”

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s expectations respecting the patent exclusivity period; commencement of the second Phase 3 study, EMBRACE, in mid-2025; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company’s profile on SEDAR+ www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

[email protected] – or – [email protected]

KEYWORDS: United States North America Canada

INDUSTRY KEYWORDS: Alternative Medicine Mental Health Health Neurology Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution

GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress™ in Amsterdam, The Netherlands. The presentation focuses on the use of the MASH Resolution Index (MASHResInd) algorithm to predict MASH resolution on biopsy in patients treated with pemvidutide, Altimmune’s 1:1 GLP-1/glucagon dual receptor agonist.

Developed by Dr. Rohit Loomba, Professor of Medicine, Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California San Diego, MASHResInd is a composite score incorporating multiple non-invasive tests, including MRI proton-density-fat-fraction (MRI-PDFF), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels for predicting MASH resolution on biopsy. Applied to datasets from a previously completed trial with pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD), the MASHResInd predicted a high probability that MASH resolution would occur with pemvidutide treatment.

“These findings underscore the potential of pemvidutide to achieve meaningful histologic improvements in MASH using non-invasive, reproducible biomarkers,” said Dr. Loomba. “We are encouraged by the significant response in the MASHResInd model, which may suggest a high likelihood of achieving MASH resolution in Altimmune’s IMPACT Phase 2b Trial of pemvidutide.”

Key Data Highlights:

The composite MASHResInd score is a robust, non-invasive marker for liver histology improvement, with potential application across clinical research and practice. In the analyses presented at EASL, 24 weeks of treatment with pemvidutide resulted in MASHResInd responses (defined as an index ≥ -0.67) in 69.2%, 92.3% and 90.9% of subjects receiving 1.2 mg (p<0.05), 1.8 mg (p<0.001), and 2.4 mg (p<0.001) of pemvidutide, respectively, compared with 22.2% in subjects receiving placebo.

“This analysis of patients from our study of pemvidutide in MASLD further reinforces our excitement around the upcoming IMPACT readout, which remains on track to be reported this quarter,” added Scott Harris, M.D., Chief Medical Officer of Altimmune. “Our MASLD trial achieved class-leading reductions in liver fat content, which is recognized to be a primary driver for MASH resolution and fibrosis improvement. The MASHResInd response rates greater than 90% at the 1.8 and 2.4 mg pemvidutide doses give us further confidence in the ability of pemvidutide to achieve statistical significance in the 24-week biopsy-based endpoints of the IMPACT Trial.”

Presentation Details



Title:

MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)

Presenter: Shaheen Tomah, M.D., Director, Clinical Development, Altimmune



Poster Tour Presentation:

  • Session: MASLD: Therapy, Track Hub 7 – Metabolism, Alcohol, and Toxicity (Poster# SAT-453)
  • Date/Time: Thursday, May 8, 2025, at 9:45 am CET


General Poster Session Presentation:

  • Session: MASLD Therapy Section (Poster# SAT-453)
  • Date/Time: Saturday, May 10, 2025, from 12:00 PM to 1:00 PM CET

The posters presented at the EASL International Liver Congress™ 2025 will be accessible on the Events section of the Altimmune website.

About Pemvidutide

Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of obesity, MASH, alcohol use disorder (AUD) as well as alcohol liver disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial. IND applications in AUD and ALD have received FDA clearance with Phase 2 trials to commence in mid-2025.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on

LinkedIn


Follow @AltimmuneInc on

X

Company Contact:

Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]

Media Contact:

Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
[email protected]

This press release was published by a CLEAR® Verified individual.



Caliber Announces First Quarter 2025 Earnings Release & Conference Call

SCOTTSDALE, Ariz., May 08, 2025 (GLOBE NEWSWIRE) — Caliber (NASDAQ: CWD), a real estate investor, developer, and manager, today announced that it will release its first quarter 2025 financial results after the close of the market on Thursday, May 15, 2025. Management invites all interested parties to its webcast/conference call the same day at 5:00 pm ET to discuss the results.

Investors and interested parties can access the live earnings call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) and ask to join the Caliber call or use conference ID 8746759.

To listen to the call online, investors can visit the investor relations page of Caliber’s website at https://ir.caliberco.com/. The webcast replay of the conference call will be available on Caliber’s website shortly after the call concludes.

Additional details:

The news release and presentation materials will also be available on the Investor Relations site under “Financial Results”.

About Caliber (CaliberCos Inc.)

With over $2.9 billion in Managed Assets, Caliber’s 16-year track record of managing and developing real estate is built on a singular goal: to make money in all market conditions, specializing in hospitality, multi-family residential, and multi-tenant industrial. Our growth is fueled by performance and a key competitive advantage: we invest in projects, strategies, and geographies that global real estate institutions often overlook. Integral to this advantage is our in-house shared services group, which gives Caliber greater control over our real estate and enhanced visibility into future investment opportunities. There are multiple ways to participate in Caliber’s success: invest in Nasdaq-listed CaliberCos Inc. and/or invest directly in our Private Funds.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the Company’s public offering filed with the SEC and other reports filed with the SEC thereafter. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

CONTACTS:
Caliber Investor Relations:
Ilya Grozovsky
+1 480-214-1915
[email protected]



REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

PR Newswire


ROCKVILLE, Md.
, May 8, 2025 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. The presentations highlight REGENXBIO’s leading end-to-end capabilities across research and early development, late-stage clinical development, and gene therapy manufacturing.

Presentations include encore data from late-stage clinical trials of RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as preclinical research supporting the novel construct of RGX-202 with the C-Terminal domain, capsid discovery research, and RGX-202 manufacturing process development enabling industry-leading purity levels in Duchenne gene therapy.


Oral Presentations:


Abstract Title: Development of a Commercial Manufacturing Process for RGX-202, a Systemically Delivered AAV for the Treatment of Duchenne Muscular Dystrophy
Presenter: Donald Startt, Executive Director, Process Development, REGENXBIO
Session: AAV Vector Manufacturing: Process Development
Date/Time: May 13, 1:30 p.m. CT

Abstract Title: RGX-121 (clemidsogene lanparvovec): an Investigational AAV Gene Therapy for the Treatment of Neuronopathic Mucopolysaccharidosis Type II
Presenter: Olivier Danos, Ph.D., Executive Vice President, Chief Scientific Officer, REGENXBIO
Session: CNS Gene Delivery for Metabolic Diseases: History and Challenges
Date/Time: May 14, 8:00 a.m. CT

Abstract Title: RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical Data
Presenter: Olivier Danos, Ph.D., Executive Vice President, Chief Scientific Officer, REGENXBIO
Session: Gene Therapy Trials: In-Vivo Gene Therapy Modification
Date/Time: May 16, 3:45 p.m. CT


Poster Presentations:


Abstract Title: Impact of Sample Collection Container Material, Hold Time, and Storage Temperature on Adeno-Associated Virus Endotoxin Testing
Presenter: Amanda Zhang, Associate Director Vectore Core, REGENXBIO
Session: Tuesday Poster Session
Date/Time: May 13, 6:00 p.m. CT

Abstract Title: AAV-Expressed Microdystrophin Containing Extended C-Terminus Improves Muscle Function and Protects Against Injury in a Mouse Model of Duchenne Muscular Dystrophy
Presenter: Benjamin Heithoff, Ph.D., Scientist II, REGENXBIO
Session: Wednesday Poster Session
Date/Time: May 14, 5:30 p.m. CT

Abstract Title: Development of In Vitro Methods for the Analysis of TLR9 Stimulation by AAV Vector Genomes
Presenter: Justin Glenn, Ph.D., Senior Scientist, REGENXBIO
Session: Wednesday Poster Session
Date/Time: May 14, 5:30 p.m. CT

Abstract Title: In Vitro and In Vivo Characterization of Oversized AAV Vectors with High Genome Integrity that Encode Microdystrophins with Extended C-Terminal Sequences
Presenter: Randolph Qian, Ph.D., Senior Scientist, REGENXBIO
Session: Wednesday Poster Session
Date/Time: May 14, 5:30 p.m. CT

Abstract Title: Blood-Brain Barrier Crossing AAV Vectors Targeting the Transferrin Receptor Engineered Using Two Different Approaches
Presenter: Elad Firnberg, Ph.D., Principal Scientist, REGENXBIO
Session: Thursday Poster Session
Date/Time: May 15, 5:30 p.m. CT

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO’s AAV platform, including those receiving Novartis’ ZOLGENSMA®. REGENXBIO’s investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit
www.REGENXBIO.com.

FORWARD-LOOKING STATEMENTS
This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “assume,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO’s future operations and clinical trials. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO’s expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie or Nippon Shinyaku, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of REGENXBIO’s Annual Report on Form 10-K for the year ended December 31, 2024, and comparable “risk factors” sections of REGENXBIO’s Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC’s website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Zolgensma® is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.

CONTACTS: 

Dana Cormack

Corporate Communications
[email protected] 

George E. MacDougall

Investor Relations
[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene–cell-therapy-28th-annual-meeting-302449753.html

SOURCE REGENXBIO Inc.

Justin’s Expands its Portfolio of Organic Chocolate Treats with Candy Bars that Meet Consumer Demand for Mindful Options

PR Newswire

Justin’s new Dark and Milk Chocolate Candy Bars will hit store shelves nationally this summer at

Sprouts Farmers Market and Whole Foods Market and will be on display for other retailers to discover
next week at Sweets & Snacks Expo


BEDMINSTER, N.J.
, May 8, 2025 /PRNewswire/ — Justin’s, a category leader known for crafting delicious, real-food products that contribute to the world in a positive and meaningful way, today is celebrating its newest confections innovation – Justin’s® Peanut Caramel Nougat Chocolate Candy Bars – offering consumers a nostalgic, organic chocolate treat made with simple ingredients. The candy bars are USDA-certified organic and Non-GMO Project Verified, and will be available in two varieties, Dark Chocolate Peanut Caramel Nougat and Milk Chocolate Peanut Caramel Nougat.

There to satisfy all cravings no matter when they arise – from a moment of relaxation to crunch time – the new candy bars will be offered in both a 1.4 ounce single-serve format with an MSRP of $2.49–$2.79, and 4.2 ounce multi-serve pouches containing six individually-wrapped, mini-size bars with an MSRP of $6.79–$7.49. The candy bars will hit shelves this summer at Sprouts Farmers Market, with additional retailers following throughout the year, including Whole Foods Market in August.

“As consumer demand for simple ingredient treats grows, we’re delighted to provide both new and loyal fans alike with a new way to enjoy Justin’s® organic chocolate treats in nostalgic and beloved formats,” said Jenny Burns, senior director of brand equity at Justin’s. “We’ve seen strong retailer interest for thecandy bars from our long-time retail partners like Sprouts and Whole Foods, and are looking forward to partnering with them and others to offer shoppers another permissible indulgence they’ve been craving.”

Between 2021 and 2024, the percentage of self-described health-conscious snackers in the U.S. has grown by more than 14%.1 Additionally, one in four consumers report they are snacking on healthier food items.2 These trends together provided Justin’s with the inspiration needed to expand its portfolio of confections to offer consumers delicious candy bars made with simple, mindfully-sourced organic ingredients they can feel good about. Justin’s full line of confections now includes a variety of nut butter cups, chocolate candy pieces and the new candy bars, providing permissible indulgences no matter the occasion or craving.

“As a mom of four and a trusted nutrition expert, I keep a running list of mindful snacks and treats for my own family, as well as for consumers, and the new Justin’s®Candy Bars are now at the top of my list,” said Frances Largeman-Roth, RDN, nutrition expert, author of Everyday Snack Tray and Justin’s partner. “They hit the mark on my standards for high-quality ingredients and have just 8 grams of sugar per mini-size bar.”

Justin’s
® Peanut Caramel Nougat Chocolate Candy Bars will be on display at the 2025 Sweets & Snacks Expo in Indianapolis from May 13-14, 2025, at booth 6308, providing show attendees the opportunity to taste and learn more about the newest way Justin’s is leveling up the candy aisle. As the candy bars hit store shelves, consumers will be able to find the bars near them at justins.com/wheretobuy.

About Justin’s
Justin’s spreads goodness everywhere it goes with delicious nut butters and USDA-certified organic chocolate treats made from simple, mindfully-sourced ingredients that are so irresistible, it’s nuts. From the iconic squeeze packs that fuel active lifestyles with convenient nutrition, to the one-of-a-kind grind that makes its nut butters unlike any other, Justin’s works to help support a food system that makes each day and each bite better, one nut at a time. Learn more at Justins.com, Instagram.com/Justins, Facebook.com/JustinsNutButter, TikTok.com/justinsbrand and Pinterest.com/Justins.


1
 Source: YouGov 2024 US Healthy Snackers Report 2024
2 Source: Technomic Consumer Trend Reports 2025 US Snacking March 2025

MEDIA CONTACT:

Emma Feeney

SchroderHaus
(224) 545-7699
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/justins-expands-its-portfolio-of-organic-chocolate-treats-with-candy-bars-that-meet-consumer-demand-for-mindful-options-302449083.html

SOURCE Justin’s

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.

Information about the Company’s quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company’s website.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
[email protected]

Source: Clearside Biomedical, Inc.



Wellgistics Health Secures $50M Credit Facility and Launches XRP-Powered Payment Initiative

Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) — Wellgistics Health, Inc. (NASDAQ: WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner.

This XRP payment initiative is supported by Wellgistics Health’s $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.

“At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money,” said Brian Norton, CEO of Wellgistics Health. “We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that’s long been starved of all three. I believe that the future winners in healthcare won’t be the companies with the biggest buildings…they’ll be those with the fastest rails, cleanest data, and most efficient platforms. We’re betting on infrastructure…not inertia.”

Why XRP? Why Now?

We believe that there are certain advantages to integrating XRP and its related infrastructure into its healthcare ecosystem. These include, among others:

  • Speed: XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and manufacturers.
  • Cost: Less than $0.0002 per transfer vs. $10-$30 for standard bank wires.
  • Transparency: All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and auditability.
  • Scope: Supports global vendor payouts with significantly low foreign exchange and wire transfer fees.
  • Flexibility: Allows for XRP-backed lines of credit to support independent pharmacy liquidity.

These benefits will support faster vendor payments, performance-based rebates, and embedded liquidity tools for pharmacies and manufacturers in the Wellgistics ecosystem.

Use Cases Across the Ecosystem

  • Real-time settlement between pharmacies, suppliers, and manufacturers
  • Smart rebates calculated automatically based on real-world data
  • XRP-backed credit lines to enhance liquidity for independent pharmacies
  • Global vendor payouts with near-zero foreign transaction and wire costs
  • Immutable compliance layer supporting DSCSA reporting and pricing validation

“We’re working to unlock capital velocity with surgical precision,” said Mark DiSiena, CFO of Wellgistics Health. “We believe that our XRP-powered infrastructure will allow us to run leaner, faster, and with more control than any of our peers in pharma infrastructure.”

The Market Is Moving-And Wellgistics Intends to Lead

XRP is gaining momentum across global institutions, as demonstrated by the following:

  1. CME Group to launch XRP futures for institutional access

    → CME will launch cash-settled XRP futures contracts in May 2025 to meet rising institutional demand.¹
  2. Mastercard identifies XRP as a bridge currency for cross-border payments

    → Mastercard’s 2025 report highlights XRP as a top solution for global remittances and cost efficiency.²
  3. Ripple acquires prime brokerage firm Hidden Road for $1.25B

    → This landmark acquisition expands XRP’s footprint in institutional liquidity and asset servicing.³
  4. Ripple receives regulatory licensing in Dubai

    → Ripple became the first blockchain payment provider licensed by the DFSA to operate crypto-based financial services in the UAE.⁴
  5. Ripple expands real-world cross-border payment corridors in Brazil and Portugal

    → Ripple now enables live XRP-powered remittances between LATAM and Europe through its partnership with Unicâmbio.⁵

“Others are waiting for change. We’re building it,” Norton added. “I strongly believe that our XRP initiative positions Wellgistics Health years ahead of the curve-and squarely at the center of where healthcare and fintech converge.”

About Wellgistics Health

Wellgistics Health, Inc. (NASDAQ:WGRX) is a publicly traded healthcare infrastructure company transforming how medications move, get priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a growing network of more than 6,000 independent pharmacies nationwide.

Wellgistics Health delivers real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment models, while equipping pharmacies with embedded financial, clinical, and digital tools. Its integrated platform supports a wide range of therapeutic categories-from specialty-lite to maintenance meds-by eliminating friction, accelerating reimbursements, and creating direct, transparent pathways between manufacturers, providers, pharmacies, and patients.

For more information, visit: www.wellgisticshealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health’s statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health’s filings with the SEC, which are available for review at www.sec.gov.

Media Contact:
[email protected]

Investor Relations:
[email protected]

References

  1. CME Group Press Release: CME to Launch XRP Futures
  2. AInvest: Mastercard Identifies XRP as Bridge Currency
  3. Reuters: Ripple Acquires Hidden Road for $1.25B
  4. BusinessWire: Ripple Licensed by DFSA in Dubai
  5. PYMNTS: Ripple Launches Portugal-Brazil Corridor



ConocoPhillips announces Bill Bullock to retire after 39 years with the company

ConocoPhillips announces Bill Bullock to retire after 39 years with the company

HOUSTON–(BUSINESS WIRE)–
ConocoPhillips (NYSE: COP) today announced that W.L. (Bill) Bullock, executive vice president and chief financial officer, will retire from ConocoPhillips after 39 years of distinguished service. Andy O’Brien, currently senior vice president, Strategy, Commercial, Sustainability and Technology, will succeed Bill as chief financial officer, effective June 1, 2025. Andy will also retain responsibility for Strategy, Commercial and Sustainability.

Bill began his career with Conoco in 1986 and held numerous engineering, operations, commercial, and business development roles of increasing responsibility before joining the company’s executive leadership team in 2018 and becoming chief financial officer in 2020.

“I want to thank Bill for his outstanding leadership, dedication and significant contributions over the course of his distinguished career at ConocoPhillips,” said Ryan Lance, chairman and chief executive officer. “Bill has contributed to virtually every area of our business, working in many locations across our global portfolio. I wish Bill the very best in retirement and look forward to Andy’s ongoing leadership as he assumes his new role.”

— # # # —

About ConocoPhillips

As a leading global exploration and production company, ConocoPhillips is uniquely equipped to deliver reliable, responsibly produced oil and gas. Our deep, durable and diverse portfolio is built to meet growing global energy demands. Together with our high-performing operations and continuously advancing technology, we are well positioned to deliver strong, consistent financial results, now and for decades to come.

For more information, go towww.conocophillips.com.

CAUTIONARY STATEMENT FOR THE PURPOSES OF THE “SAFE HARBOR” PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.

This news release contains forward-looking statements as defined under the federal securities laws. Forward-looking statements relate to future events, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues, costs and plans, objectives of management for future operations, the anticipated benefits of our acquisition of Marathon Oil Corporation (Marathon Oil), the anticipated impact of our acquisition of Marathon Oil on the combined company’s business and future financial and operating results and the expected amount and timing of synergies from our acquisition of Marathon Oil and other aspects of our operations or operating results. Words and phrases such as “ambition,” “anticipate,” “believe,” “budget,” “continue,” “could,” “effort,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “predict,” “projection,” “seek,” “should,” “target,” “will,” “would,” and other similar words can be used to identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. Where, in any forward- looking statement, the company expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future performance and involve certain risks, uncertainties and other factors beyond our control. Therefore, actual outcomes and results may differ materially from what is expressed or forecast in the forward-looking statements. Factors that could cause actual results or events to differ materially from what is presented include, but are not limited to, the following: effects of volatile commodity prices, including prolonged periods of low commodity prices, which may adversely impact our operating results and our ability to execute on our strategy and could result in recognition of impairment charges on our long-lived assets, leaseholds and nonconsolidated equity investments; global and regional changes in the demand, supply, prices, differentials or other market conditions affecting oil and gas, including changes as a result of any ongoing military conflict and the global response to such conflict, security threats on facilities and infrastructure, global health crises, the imposition or lifting of crude oil production quotas or other actions that might be imposed by OPEC and other producing countries or the resulting company or third-party actions in response to such changes; the potential for insufficient liquidity or other factors, such as those described herein, that could impact our ability to repurchase shares and declare and pay dividends, whether fixed or variable; potential failures or delays in achieving expected reserve or production levels from existing and future oil and gas developments, including due to operating hazards, drilling risks and the inherent uncertainties in predicting reserves and reservoir performance; reductions in our reserve replacement rates, whether as a result of significant declines in commodity prices or otherwise; unsuccessful exploratory drilling activities or the inability to obtain access to exploratory acreage; failure to progress or complete announced and future development plans related to constructing, modifying or operating related to constructing, modifying or operating E&P and LNG facilities, or unexpected changes in costs, inflationary pressures or technical equipment related to such plans; significant operational or investment changes imposed by legislative and regulatory initiatives and international agreements addressing environmental concerns, including initiatives addressing the impact of global climate change, such as limiting or reducing GHG emissions, regulations concerning hydraulic fracturing, methane emissions, flaring or water disposal and prohibitions on commodity exports; broader societal attention to and efforts to address climate change may cause substantial investment in and increased adoption of competing or alternative energy sources; risks, uncertainties and high costs that may prevent us from successfully executing on our Climate Risk Strategy; lack or inadequacy of, or disruptions in reliable transportation for our crude oil, bitumen, natural gas, LNG and NGLs; inability to timely obtain or maintain permits, including those necessary for construction, drilling and/or development, or inability to make capital expenditures required to maintain compliance with any necessary permits or applicable laws or regulations; potential disruption or interruption of our operations and any resulting consequences due to accidents, extraordinary weather events, supply chain disruptions, civil unrest, political events, war, terrorism, cybersecurity threats or information technology failures, constraints or disruptions; liability for remedial actions, including removal and reclamation obligations, under existing or future environmental regulations and litigation; liability resulting from pending or future litigation or our failure to comply with applicable laws and regulations; general domestic and international economic, political and diplomatic developments, including deterioration of international trade relationships, the imposition of trade restrictions or tariffs relating to commodities and material or products (such as aluminum and steel) used in the operation of our business, expropriation of assets, changes in governmental policies relating to commodity pricing, including the imposition of price caps, sanctions or other adverse regulations or taxation policies; competition and consolidation in the oil and gas E&P industry, including competition for sources of supply, services, personnel and equipment; any limitations on our access to capital or increase in our cost of capital or insurance, including as a result of illiquidity, changes or uncertainty in domestic or international financial markets, foreign currency exchange rate fluctuations or investment sentiment; challenges or delays to our execution of, or successful implementation of the acquisition of Marathon Oil or any future asset dispositions or acquisitions we elect to pursue; potential disruption of our operations, including the diversion of management time and attention; our inability to realize anticipated cost savings or capital expenditure reductions; difficulties integrating acquired businesses and technologies; or other unanticipated changes; our inability to deploy the net proceeds from any asset dispositions that are pending or that we elect to undertake in the future in the manner and timeframe we anticipate, if at all; the operation, financing and management of risks of our joint ventures; the ability of our customers and other contractual counterparties to satisfy their obligations to us, including our ability to collect payments when due from the government of Venezuela or PDVSA; uncertainty as to the long-term value of our common stock; and other economic, business, competitive and/or regulatory factors affecting our business generally as set forth in our filings with the Securities and Exchange Commission. Unless legally required, ConocoPhillips expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Dennis Nuss (media)

281-293-1149

[email protected]

Investor Relations

281-293-5000

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo